A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Study Summary

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).

Conditions

Chronic Obstructive Pulmonary Disease

Interventions / Drugs

Ensifentrine 3 mg Glycopyrrolate 21.25 mcg Glycopyrrolate 42.5 mcg Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment480 participants

Primary Completion—

Lead SponsorVerona Pharma plc

Data Retrieved2026-04-11 04:31:16.186906+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.